Eltrombopag 12.5 mg ( DrugBank: Eltrombopag )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
60	再生不良性貧血	1

60. 再生不良性貧血

---

臨床試験数 : 235 /  薬物数 : 381 - (DrugBank : 83) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 160

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02148133 (ClinicalTrials.gov)	July 23, 2014	22/5/2014	A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia	A Non-randomized, Open-label, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia	Cytopaenia	Drug: Eltrombopag 12.5 mg;Drug: Eltrombopag 25 mg	Novartis Pharmaceuticals	NULL	Completed	18 Years	79 Years	All	21	Phase 2	Japan